Michelle Baxter

DEIB, Change, Leadership & Relationships. Psych & Gender. All opinions are my own. RT/follows do not imply endorsement.

[Michelle Baxter @MichelleBxtr]

Success is liking yourself, liking what you do, and liking how you do it. ~Maya Angelou

[Michelle Baxter @MichelleBxtr]

@ecomchigga HIRE ME

[Michelle Baxter @MichelleBxtr]

@davidfigeira AFF

[Dr Iain McGilchrist @dr_mcgilchrist]

Iain McGilchrist and Charles Eisenstein in conversation – Being in the World Today – 4th June 2026: 5pm to 6.30pm (UK Time)
At the recent meeting in Oxford on The Good, The Beautiful, and The True, Iain spoke about being in the world – how to be in the world – as the essential role of education, and what he had learned from his inspiring teachers.
Location: online
Thursday, June 4th from 5PM to 6.30PM (UKTime)
This is a free event but you must register to receive the link. Follow this link https://t.co/t7WIkrhJZo

[BLab Coats @BLabCoats]

Women on temporary visa have no protection against domestic violence. This issue is ignored too often. Tomorrow we release a documentary and interview with a DV survivor, Yuliia.

#Domesticviolence #DV
#domesticviolencesurvivor

[Michael Levin @drmichaellevin]

New #preprint: an exciting and new aspect of #bioelectricity!

Most work on bioelectricity and electrophysiology focuses on events at the cell membrane. Here, we (@HamidSediqi18 , @cellbioelectric, et al.) tackle a new aspect of the electric dimension of cells: the nuclear membrane.

https://t.co/Xwlop6aUC7

"Ionic Exposure History Shapes Inner Nuclear Membrane Voltage and Chromatin Texture Responses"

We created a new reagent for monitoring the voltage across the nuclear envelope, finding changes in chromatin and ordering effects (i.e., a kind of simple memory of past experiences) in its response to ionic stimuli. This is just the beginning - a new target for monitoring and interventions that I predict will have a lot of impact on nuclear events (chromatin state, gene expression, etc.) and thus cell behavior.

[Michelle Baxter @MichelleBxtr]

@TommiPedruzzi KDP

[Michelle Baxter @MichelleBxtr]

@eCom_Amin Manus

[Michelle Baxter @MichelleBxtr]

@jordan_ross_8F 4M

[Michelle Baxter @MichelleBxtr]

@0xROAS PAPER

[Michelle Baxter @MichelleBxtr]

@NickDiFabio1 Claude

[Michelle Baxter @MichelleBxtr]

@TommiPedruzzi Doc

[stranger @strangerous10]

Exposed: Pauline Hanson in Hot Water as official identified as white supremacist who defends Nazi Hitler Youth, advocates White Australia Policy & spews racist bile online. Says he’s “proud” to work for Hanson. Clearly fits in.
This is the rot at the heart of One Nation. #auspol

[Michelle Baxter @MichelleBxtr]

@mikefutia Ads

[Michelle Baxter @MichelleBxtr]

@kevin_parker_ai AI

[Michelle Baxter @MichelleBxtr]

@itspriionly PROMPT

[Priyansh @itspriionly]

NO ONE teaches you how to use Claude with professional-level prompts.

I gathered 300 Prompts to turn it into your best employee.

(ALL CATEGORIES)

Like + RT + follow me

Comment "PROMPT" and I'll send them to you via DM.

[Michelle Baxter @MichelleBxtr]

@X_FINALBOSS MASTERCLASS

[Michelle Baxter @MichelleBxtr]

@Bogzabs96 Hook

[Lifespan @JoinLifespan]

Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀

Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman

The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases

The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression

“This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.”

Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential.

“This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.”

Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment

Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies.

Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform.

About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults

While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments

About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at https://t.co/GDRzIctoot (NCT07290244): https://t.co/Jj9cnu2M6w

For more information, visit https://t.co/msih0JTYfF or follow on social media
https://t.co/pEGPJjFjnQ

[Adam J. Eisen @adamjeisen]

How do brain areas control each other? 🧠🎛️

✨In our NeurIPS 2025 Spotlight paper, we introduce a data-driven framework to answer this question using deep learning, nonlinear control, and differential geometry.🧵⬇️

@neurostrow @SarthakChandra @Leokoz8 @MillerLabMIT @FieteGroup